1.Influence of Musa sapientum L. on pharmacokinetic of metformin in diabetic gastroparesis.
Vaibhav DARVHEKAR ; Alok Shiomurti TRIPATHI ; Shriramji G JYOTISHI ; Papiya Mitra MAZUMDER ; Pradeep G SHELKE
Chinese journal of integrative medicine 2016;22(10):783-788
OBJECTIVETo investigate the effect of Musa sapientum L. (MS) bark juice in diabetic gastroparesis and its effect on pharmacokinetic of metformin (MET).
METHODSDiabetes was induced in rats by administering alloxan (120 mg/kg) saline solution and maintained for 8 week. All the 18 Sprague-Dawley rats were divided into three groups (n =6 in each group): normal control, diabetic control and MS bark juice. Assessment of diabetes was done by glucose oxidase-peroxidase method on the 3rd day of alloxan administration. The effects of MS bark juice (100 mL/kg) on gastric emptying time, intestinal transit time, contractility of fundus and pylorus as well as gastric acid secretion in chronic diabetic rats were observed after 8 weeks of alloxan administration. The effect of MS bark juice on the pharmacokinetic of orally administered single dose of MET (350 mg/kg) was evaluated on the 57th day of protocol. Any drugs that may reduce the blood glucose level or influence the fibrinolytic system were not used in this study.
RESULTSThe MS bark juice significantly reduced the blood glucose level in the diabetic rats (P<0.01). There was significant decrease in the pylorus motility and increase in the gastric emptying time, intestinal transit time, contractility of fundus, gastric acid secretion in the MS bark juice treated group (P<0.01). There was significant decrease in the time at which drug at a maximum concentration, half life of drug and increase in the maximum concentration of drug in the plasma of MET in MS bark juice treated group as compared to diabetic control group (P<0.01).
CONCLUSIONMS bark juice effectively manages diabetic gastroparesis and thereby improves the bioavailabilty of MET when administered with MS bark juice.
Alloxan ; Animals ; Blood Glucose ; Chromatography, High Pressure Liquid ; Diabetes Mellitus, Experimental ; blood ; complications ; drug therapy ; physiopathology ; Gastroparesis ; blood ; complications ; drug therapy ; physiopathology ; Male ; Metformin ; blood ; pharmacokinetics ; therapeutic use ; Musa ; chemistry ; Plant Extracts ; pharmacology ; therapeutic use ; Rats, Sprague-Dawley
2.Effect of Qingre Yangyin Recipe on Endocrine and Metabolism of Polycystic Ovary Syndrome Patients.
Chinese Journal of Integrated Traditional and Western Medicine 2015;35(10):1175-1180
OBJECTIVETo observe the effect of Qingre Yangyin Recipe (QRYYR) on sex hormones and insulin resistance (IR) in polycystic ovary syndrome (PCOS) patients.
METHODSTotally 90 PCOS patients were randomly assigned to the Chinese herbs group,the Western medicine group, the combined group, 30 in each group. Patients in the Chinese herbs group took QRYYR, one dose per day in two portions, once in the morning and once in the evening. Patients in the Western medicine group took Metformin 500 mg, twice per day for 3 consecutive months. Patients in the combined group took QRYYR and Metformin (the same as the former said two groups) in the 1st month, and took QRYYR for the following two months. Fasting blood glucose (FPG) and postprandial 2 h blood glucose (2 h GLU) were determined using hexokinase method before and after treatment. Fasting insulin (FINS), postprandial 2 h insulin (2 h INS), luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2), progesterone (P), prolactin (PRL), and testosterone (T) were detected using chemiluminescent method. Leptin and adiponectin (APN) were determined using ELISA. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Body weight and height were measured once before treatment and once after treatment to calculate body mass index (BMI). The total two-phase basal body temperature (BBT) actually obtained within 3 months was statistically collected to calculate the two-phase BBT rate. Scores for Chinese medical syndromes were compared between the two groups before and after treatment.
RESULTSCompared with before treatment in the same group, BMI, FINS, 2 h INS, HOMA-IR, leptin, LH, PRL, T, and scores for Chinese medical syndromes obviously decreased, and APN levels increased (P < 0.05). FPG and 2 h FPG obviously decreased in the Western medicine group and the combined group (P < 0.05). E2 levels obviously decreased in the combined group with statistical difference (P < 0.05). Compared with the Chinese herbs group, the difference of BMI between pre-treatment and post-treatment was more in the combined group (P < 0.05). The difference of FPG,2 h GLU, 2 h INS, HOMA-IR, and APN between pre-treatment and post-treatment was more in the Chinese herbs group and the combined group (P < 0.05). Compared with the Western medicine group, the difference of PRL, T, and scores for Chinese medical syndromes was more in the Western medicine group and the combined group (P < 0.05); the difference of E2 and LH was even more in the combined group (P < 0.05). Compared with the combined group, the biphasic rate was obviously lowered in the Western medicine group (P < 0.05).
CONCLUSIONSQRYYR could improve IR but with weaker power to that of Metformin. It also could decrease serum levels of LH, T, PRL, and scores for Chinese medical syndromes, with superior effect to that of Metformin. The effect in the combined group was better.
Adiponectin ; Blood Glucose ; Body Mass Index ; Drugs, Chinese Herbal ; pharmacology ; therapeutic use ; Estradiol ; Female ; Follicle Stimulating Hormone ; Gonadal Steroid Hormones ; Humans ; Insulin ; Insulin Resistance ; Leptin ; Luteinizing Hormone ; Metformin ; Polycystic Ovary Syndrome ; drug therapy ; metabolism ; Progesterone ; Prolactin ; Testosterone
3.Metformin improves polycystic ovary syndrome and activates female germline stem cells in mice.
Chun-Hong WANG ; Qiang-Qiang WANG ; Ya-Shan SU ; Ya-Qun SUN ; Miao SUN ; Xin-Rui LIU ; Hui-Ming MA ; Guang-Yong LI ; Xiao-Li DU ; Rui HE
Acta Physiologica Sinica 2022;74(3):370-380
Polycystic ovary syndrome (PCOS) is a common disease caused by complex endocrine and metabolic abnormalities in women of childbearing age. Metformin is the most widely used oral hypoglycemic drug in clinic. In recent years, metformin has been used in the treatment of PCOS, but its mechanism is not clear. In this study, we aimed to investigate the effect of metformin on PCOS and its mechanism through PCOS mouse model. Female C57BL/6J mice aged 4-5 weeks were intragastrically given letrozole (1 mg/kg daily) combined with a high-fat diet (HFD) for 21 days to establish the PCOS model. After modeling, metformin (200 mg/kg daily) was intragastrically administered. One month later, the body weight and oral glucose tolerance test (OGTT) were measured. Hematoxylin eosin (H&E) staining was used to detect the pathological changes of ovary. The serum levels of anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2 and testosterone (T) were measured by ELISA. The expression of DDX4/MVH was detected by immunohistochemistry. DDX4/MVH and PCNA were co-labeled by immunofluorescence. The protein levels of DDX4/MVH, PCNA, cyclin D2, AMPK and mTOR were detected by Western blot. The results showed that after metformin treatment, the body weights of PCOS mice were gradually returned to normal, glucose tolerance was significantly improved, serum E2 levels were increased, while AMH, LH, T levels and LH/FSH ratio were decreased. Ovarian polycystic lesions were reduced with reduced atresia follicles. Furthermore, the number of proliferative female germline stem cells (FGSCs) and levels of proliferation related proteins (PCNA, cyclin D2) were significantly increased, and the p-mTOR and p-AMPK levels were markedly up-regulated. These results suggest that metformin treatment not only improves hyperandrogenemia, glucose intolerance and polycystic ovarian lesions in PCOS, but also activates the function of FGSCs. The underlying mechanism may be related to the phosphorylation of AMPK and mTOR. These findings provide new evidence to use metformin in the treatment of PCOS and follicular development disorder.
AMP-Activated Protein Kinases
;
Animals
;
Cyclin D2
;
Female
;
Follicle Stimulating Hormone/therapeutic use*
;
Humans
;
Luteinizing Hormone/therapeutic use*
;
Metformin/pharmacology*
;
Mice
;
Mice, Inbred C57BL
;
Oogonial Stem Cells/metabolism*
;
Ovarian Cysts/drug therapy*
;
Ovarian Neoplasms
;
Polycystic Ovary Syndrome/drug therapy*
;
Proliferating Cell Nuclear Antigen/therapeutic use*
;
TOR Serine-Threonine Kinases
4.Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
Tae Jung OH ; Ji Yon SHIN ; Gyeong Hoon KANG ; Kyong Soo PARK ; Young Min CHO
Experimental & Molecular Medicine 2013;45(7):e30-
Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-alpha-dependent manner. We investigated whether a PPARalpha agonist, fenofibrate, exhibits an additive or synergistic effect on glucose metabolism, independent of its lipid-lowering effect, when added to metformin. Non-obese diabetic Goto-Kakizaki (GK) rats were divided into four groups and treated for 28 days with metformin, fenofibrate, metformin plus fenofibrate or vehicle. The random blood glucose levels, body weights, food intake and serum lipid profiles were not significantly different among the groups. After 4 weeks, metformin, but not fenofibrate, markedly reduced the blood glucose levels during oral glucose tolerance tests, and this effect was attenuated by adding fenofibrate. Metformin increased the expression of the GLP-1 receptor in pancreatic islets, whereas fenofibrate did not. During the intraperitoneal glucose tolerance tests with the injection of a GLP-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. In conclusion, fenofibrate did not confer any beneficial effect on glucose homeostasis but reduced metformin's glucose-lowering activity in GK rats, thus discouraging the addition of fenofibrate to metformin to improve glycemic control.
Animals
;
Blood Glucose/metabolism
;
Body Weight/drug effects
;
Diabetes Mellitus, Experimental/*drug therapy/*metabolism
;
Drug Therapy, Combination
;
Feeding Behavior/drug effects
;
Fenofibrate/*pharmacology/therapeutic use
;
Glucagon-Like Peptide 1/agonists/metabolism
;
Glucose/*metabolism
;
Glucose Tolerance Test
;
Homeostasis/*drug effects
;
Immunohistochemistry
;
Injections, Intraperitoneal
;
Insulin-Secreting Cells/drug effects/metabolism/pathology
;
Lipid Metabolism/drug effects
;
Male
;
Metformin/*pharmacology/therapeutic use
;
Peptides/administration & dosage/pharmacology
;
Rats
;
Receptors, Glucagon/metabolism
;
Venoms/administration & dosage/pharmacology
5.Effect of Aspirin on the Expression of Hepatocyte NF-kappaB and Serum TNF-alpha in Streptozotocin-Induced Type 2 Diabetic Rats.
Xiaodong SUN ; Fang HAN ; Junling YI ; Lina HAN ; Ben WANG
Journal of Korean Medical Science 2011;26(6):765-770
Aspirin is a kind of anti-inflammatory drug and may be used to reverse hyperglycemia, hyperinsulinemia, and dyslipidemia by improving insulin resistance. We hypothesized that aspirin improves insulin resistance in type 2 diabetes by inhibiting hepatic nuclear factor kappa-beta (NF-kappaB) activation and serum tumor necrosis factor-alpha (TNF-alpha). Adult male Wistar rats were randomly divided into four groups: control, untreated diabetic, diabetic treated with metformin (100 mg/kg/day), and diabetic treated with aspirin (120 mg/kg/day). Diabetes was induced by high-fat feeding and a low dose of streptozotocin (30 mg/kg). After treatment, plasma glucose, insulin, lipids, free fatty acids (FFAs) concentrations and serum TNF-alpha were determined. The expression of NF-kappaB in hepatocytes was analyzed by immunohistochemistry and western blot. The results showed administration of aspirin caused no significant lowering in fasting glucose level but significant reduction of hepatic NF-kappaB expression and serum TNF-alpha level with improved insulin resistance compared to the diabetic group. The relevant analysis showed positive correlation between the expression of homeostasis model assessment-insulin resistance (HOMA-IR) and NF-kappaB (r = 0.799, P < 0.01); HOMA-IR and serum TNF-alpha (r = 0.790, P < 0.01). It is concluded that aspirin improves insulin resistance by inhibiting hepatic NF-kappaB activation and TNF-alpha level in streptozotocin-induced type 2 diabetic rats.
Animals
;
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
;
Aspirin/*pharmacology
;
Blood Glucose/analysis
;
Diabetes Mellitus, Experimental/blood/chemically induced/*metabolism
;
Fatty Acids, Nonesterified/blood
;
Hypoglycemic Agents/*pharmacology
;
Insulin/blood
;
Insulin Resistance
;
Liver/metabolism
;
Male
;
Metformin/therapeutic use
;
NF-kappa B/*metabolism
;
Rats
;
Rats, Wistar
;
Tumor Necrosis Factor-alpha/*blood
6.Chronic Intracerebroventricular Infusion of Metformin Inhibits Salt-Sensitive Hypertension via Attenuation of Oxidative Stress and Neurohormonal Excitation in Rat Paraventricular Nucleus.
Xiao-Jing YU ; Ya-Nan ZHAO ; Yi-Kang HOU ; Hong-Bao LI ; Wen-Jie XIA ; Hong-Li GAO ; Kai-Li LIU ; Qing SU ; Hui-Yu YANG ; Bin LIANG ; Wen-Sheng CHEN ; Wei CUI ; Ying LI ; Guo-Qing ZHU ; Zhi-Ming YANG ; Yu-Ming KANG
Neuroscience Bulletin 2019;35(1):57-66
Metformin (MET), an antidiabetic agent, also has antioxidative effects in metabolic-related hypertension. This study was designed to determine whether MET has anti-hypertensive effects in salt-sensitive hypertensive rats by inhibiting oxidative stress in the hypothalamic paraventricular nucleus (PVN). Salt-sensitive rats received a high-salt (HS) diet to induce hypertension, or a normal-salt (NS) diet as control. At the same time, they received intracerebroventricular (ICV) infusion of MET or vehicle for 6 weeks. We found that HS rats had higher oxidative stress levels and mean arterial pressure (MAP) than NS rats. ICV infusion of MET attenuated MAP and reduced plasma norepinephrine levels in HS rats. It also decreased reactive oxygen species and the expression of subunits of NAD(P)H oxidase, improved the superoxide dismutase activity, reduced components of the renin-angiotensin system, and altered neurotransmitters in the PVN. Our findings suggest that central MET administration lowers MAP in salt-sensitive hypertension via attenuating oxidative stress, inhibiting the renin-angiotensin system, and restoring the balance between excitatory and inhibitory neurotransmitters in the PVN.
Animals
;
Antioxidants
;
therapeutic use
;
Arterial Pressure
;
drug effects
;
Hypertension
;
chemically induced
;
drug therapy
;
Infusions, Intraventricular
;
Male
;
Metformin
;
administration & dosage
;
pharmacology
;
Neurotransmitter Agents
;
metabolism
;
Oxidative Stress
;
drug effects
;
Paraventricular Hypothalamic Nucleus
;
drug effects
;
Rats
;
Reactive Oxygen Species
;
metabolism
;
Sodium Chloride, Dietary
;
pharmacology
7.Effect of metformin on the formation of hepatic fibrosis in type 2 diabetic rats.
Gui-Fen QIANG ; Li ZHANG ; Qi XUAN ; Xiu-Ying YANG ; Li-Li SHI ; Heng-Ai ZHANG ; Bai-Nian CHEN ; Guan-Hua DU
Acta Pharmaceutica Sinica 2010;45(6):801-806
The aim of this study is to investigate the effects of the metformin on the formation of hepatic fibrosis in type 2 diabetic rats and discuss its mechanism of liver-protecting activity. After SD rats were fed with high-fat and high-sucrose diet for four weeks, low-dose streptozotocin (STZ) was injected intraperitoneally to make the animal mode of type 2 diabetes. Then, all diabetic rats was fed with the high-fat diet and metformin (ig, 100 mg x kg(-1)) was given orally to metformin group for four months. After the last administration, fasting blood glucose was determined. The livers were removed to calculate the hepatic coefficient and to make HE and Picro acid-Sirius red staining, immunohistochemistry (alpha-SMA and TGFbeta1) and TUNEL staining in order to evaluate the effect of metformin on the hepatic fibrosis. The animal model of type 2 diabetes with hepatic fibrosis was successfully made. Metformin can significantly alleviate the lesions of hepatic steatosis and fibrosis, markedly reduce the expressions of alpha-SMA and TGFbeta1 in liver tissue of type 2 diabetic rats. However, TUNEL staining result suggested that metformin could not reduce apoptosis of hepatocytes. The results suggest that metformin can inhibit the formation of hepatic fibrosis in type 2 diabetes.
Actins
;
metabolism
;
Animals
;
Apoptosis
;
drug effects
;
Blood Glucose
;
metabolism
;
Body Weight
;
drug effects
;
Diabetes Mellitus, Experimental
;
drug therapy
;
etiology
;
metabolism
;
pathology
;
Diabetes Mellitus, Type 2
;
drug therapy
;
etiology
;
metabolism
;
pathology
;
Diet, High-Fat
;
Female
;
Hepatocytes
;
pathology
;
Hypoglycemic Agents
;
pharmacology
;
therapeutic use
;
Liver
;
metabolism
;
pathology
;
Liver Cirrhosis, Experimental
;
drug therapy
;
metabolism
;
pathology
;
Male
;
Metformin
;
pharmacology
;
therapeutic use
;
Random Allocation
;
Rats
;
Rats, Sprague-Dawley
;
Streptozocin
;
Transforming Growth Factor beta1
;
metabolism